Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Meflowin Mefloquine Tablets IP 250 mg
Meflowin Mefloquine Tablets are formulated to combat malaria, a serious disease caused by Plasmodium parasites transmitted through mosquito bites. Mefloquine, the primary active ingredient, provides a vital option for malaria treatment and prophylaxis, especially in regions with drug-resistant strains.
Uses of Meflowin Mefloquine Tablets IP 250 mg
Malaria Treatment: Effective in treating uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax.
Malaria Prevention: Used to prevent malaria in travelers to endemic areas.
Post-Exposure Prophylaxis: Recommended for use following exposure to malaria in high-risk zones.
Benefits of Meflowin Mefloquine Tablets IP 250 mg
Effectiveness Against Resistant Strains: Useful for treating malaria strains resistant to other antimalarial medications.
Extended Protection: Provides long-lasting prophylactic coverage, making it suitable for use in areas with high malaria risk.
Convenient Dosing Schedule: Typically taken once a week for prevention, which enhances patient adherence.
Mechanism of Action of Meflowin Mefloquine Tablets IP 250 mg
Inhibits Parasite Growth: Mefloquine interferes with the metabolism of the malaria parasites, particularly by affecting the detoxification of heme, which is crucial for the parasites survival.
Parasite Elimination: Disrupts the parasites replication process within red blood cells, leading to its death.
Prophylactic Effect: Prevents the onset of malaria in individuals exposed to the parasite, thereby reducing the risk of infection.